Conversion therapy of a giant HCC with portal vein thrombus and inferior vena cava tumor thrombus

wenjie Song
Xijing Hospital, Air Force Military Medical University

jian Xu
Xijing Hospital, Air Force Military Medical University

ye Nie
Xijing Hospital, Air Force Military Medical University

weimin Li
Xijing Hospital, Air Force Military Medical University

jianping Li
Xijing Hospital, Air Force Military Medical University

li Yang
Xijing Hospital, Air Force Military Medical University

mengqi Wei
Xijing Hospital, Air Force Military Medical University

kaishan Tao (✉ taokaishan0726@163.com)
Xijing Hospital, Air Force Military Medical University

Case Report

Keywords:

Posted Date: August 23rd, 2023

DOI: https://doi.org/10.21203/rs.3.rs-3267718/v1

License: ☛ Ⓡ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The prognosis of HCC combined with portal and hepatic vein tumor thrombus is poor, with a median survival time of only about 2.7-3 months [1], and treatment requires the cooperation of the MDT team. Prof. Cheng's team gives treatment recommendations based on the classification of portal vein thrombosis and hepatic vein thrombosis. For portal vein tumor thrombus involving the main trunk of the portal vein (PVTT III) and hepatic vein tumor thrombus involving the inferior vena cava, a combination of radiotherapy, TACE, and surgical resection is recommended according to the patient's liver function [2, 3]. The combination of targeted therapy and immune therapy has progressed to become the first-line recommended treatment for advanced HCC [4]. Conversion therapy or conversion surgery (CS) is a surgical strategy developed to improve long-term survival in patients with initially unresectable tumors, aiming at R0 resection after stage reduction by non-surgical treatment [5]. CS has also been reported in HCC, radical resection of partially unresectable HCC (UR-HCC) has been achieved through transcatheter arterial chemoembolization (TACE), portal vein embolization, and oral administration of molecular targeted drugs [6, 7]. In recent years, the efficacy of atilizumab combined with bevacizumab (Atez + Bev) in the treatment of UR-HCC has been confirmed [8–10]. The above therapeutic advances have brought hope for advanced HCC, but the efficacy is still limited. In our center, a patient with giant HCC combined with portal vein tumor thrombus and hepatic vein tumor thrombus was treated with TACE, radiotherapy, targeted therapy and immunotherapy, and was continuously given Epimedium soft capsules for oral regulation. After 7 months of conversion therapy, the patient's tumor shrank and the tumor thrombus subsided significantly. The pathology of surgical resection was in complete remission, and there was no progression in the postoperative follow-up for 7 months, which provided a basis for the future strategy of combined conversion therapy.

CONCLUSION

In this case, atezolizumab, bevacizumab, icaritin soft capsules combined with radiotherapy and TACE had a good effect. For patients with hepatocellular carcinoma combined with hepatic vein/inferior vena cava tumor thrombus, adopting a high-intensity, multimodal proactive strategy under the guidance of MDT is an important attempt to break through the current treatment dilemma.

Case report

The patient was a 52-year-old man who was admitted to the hospital on April 24, 2022, with discomfort in the right upper abdomen. He had a history of hepatitis B for more than 40 years, and a solid mass of about 11.2 cm × 9.5 cm in the right lobe of the liver. The patient was considered to be a hepatocellular carcinoma (CNLC Stage a) combined with a portal vein tumor thrombus (a) and an inferior vena cava tumor thrombus ( ), with cirrhosis of the liver. (Figure
After puncture biopsy, it was confirmed as highly differentiated hepatocellular carcinoma and assessed as high risk for surgical resection. TACE treatment (Loblatin 50mg infusion) was performed first, followed by radiotherapy (48Gy for a total of 18 sessions) and 7 cycles of adjuvant treatment with atelizumab (1200mg) + bevacizumab (15mg/kg) and epimedium soft capsule (3 tablets/per session, BID). On 2022.8.17, polyvinyl alcohol embolization (pirarubicin 40mg) was performed again to consolidate the efficacy of treatment. Because of the high level of hepatitis B virus, the patient was given a full course of antiviral therapy with oral entecavir capsules one pill a day. During the whole course of treatment, the PIVKA-II decreased from 32004 to 31, and the AFP decreased from 110010 to 8.8 (Fig. 2). Significant shrinkage of the tumour can be seen by imaging changes over 7 months, with a significant reduction in the inferior vena cava from 56.6mm to 27.9m (Fig. 3). Transient transaminase elevation occurred during the treatment, and symptomatic liver-protective treatment was given.

Imaging examination showed that the tumor gradually shrunk, the portal vein tumor thrombus and the hepatic vein tumor thrombus gradually subsided, and the tumor markers AFP and PIVKA-II gradually decreased to normal levels. In November 2022, the review of the patient reached the criteria for radical surgery, and right hemihepatectomy and removal of vena cava tumor thrombus were performed. Extensive specimens were taken after surgery, the volume of the inferior vena cava tumor thrombus resection specimen was 2cmX1.5cmXcm, the cut surface was gray solid nature. The volume of the partial liver resection specimen was 13cmX10cmX5cm, and a grey nodular mass was found in the gray-yellow cut surface, which locally seems to be necrotic, area:6cmX4.5cm, peripheral with visible several lower star diameter:0.2-0.7cm. Tumor bed, right branch of portal vein and inferior vena cava were seen in large amount of necrotic material, no active tumor cells were seen. Pathologic examination showed complete remission. (Figure 4)

The patient had transient postoperative liver function abnormalities, including elevated bilirubin and transaminases, and was discharged from the hospital on the 8th postoperative day. Pathological results showed that no live hepatocellular carcinoma survived, and only necrotic tumor left. No recurrence was observed 7 months after hepatectomy, as it shown on imaging in Figure 5. The course of treatment is shown in Figure 6.

Written informed consent was obtained from the patient for the use of this case report and any accompanying images.

**Discussion**

Hepatocellular carcinoma is the sixth most common malignant tumor in the world, with about 740,000 new cases each year. Surgical treatment is an important means for patients with hepatocellular carcinoma to achieve long-term survival, but only a small number of patients have the opportunity for surgery or liver transplantation. For patients with advanced hepatocellular carcinoma, effective systemic treatment can help to reduce tumor burden, improve tumor-related symptoms, improve quality of life and prolong survival time. The prognosis of patients with hepatocellular carcinoma combined with hepatic
vein/inferior vena cava tumor thrombus is extremely poor and progress rapidly. Most of them will suffer from hepatic failure in a short period of time or die of pulmonary embolism or cardiac tamponade due to tumor thrombus abscistion. Without treatment, the median survival time of the patients is only 2.7 to 3 months [2]. Existing treatment modalities are ineffective in addressing this situation. Studies showed that advanced hepatocellular carcinoma has varying degrees of tumor shrinkage after downstage treatment. The 5-year survival rate after second-stage surgical resection or liver transplantation is 25-57%[3]. Therefore, performing downstage/conversion surgery may be one of the important means to improve the prognosis of middle and advanced stage hepatocellular carcinoma.

Due to the biological characteristics of hepatocellular carcinoma and the anatomical features of liver, hepatocellular carcinoma cells are prone to invade the intrahepatic vascular system, especially the portal vein system, and form portal vein tumor thrombus (PVTT), with an incidence of 44%-62.2%. Once PVTT occurs in patients with liver cancer, the disease develops rapidly, and intrahepatic and extrahepatic metastases, portal hypertension, jaundice, ascites and so on may occur in a short period of time.

For the treatment of advanced hepatocellular carcinoma combined with portal vein tumor embolism, the results of a study of 6474 patients published by the Japanese Liver Cancer Study Group represent a higher level of treatment: Patients who did not undergo surgical treatment had a median overall survival of 0.48 ~ 1.1 years according to the different liver function scores (Child - Pugh, A, or B), and the 1-, 3-, and 5-year survival rates were 32.2% ~ 53.1%, 13.0% ~ 25.3%, and 7.9% ~ 16.0%, respectively; for surgical patients, according to the tumor embolization classification (Japanese Society of Oncology Classification Vp 1 ~ 4) and the liver function score (Child - Pugh, A or B), the 90-d postoperative mortality rate was 2.4% ~ 8.2%, the median recurrence-free survival rate was 0.38 ~ 1.23, and the median overall survival period was 1.44 ~ 2.87 years, and 1-, 3-, and 5-year survival rates of 61.3% ~ 74.8%, 35.2% ~ 49.1%, and 25.6% ~ 39.1%, respectively [16].

There have been some findings suggesting the efficacy of selective internal radiotherapy for tumor shrinkage and its role in the translational treatment of hepatocellular carcinoma. Compared with external radiotherapy, selective internal radiotherapy has higher local dose and more accurate location for patients with portal vein tumor thrombus, and it also reduces radiation damage to normal liver tissue and has less impact on liver reserve function. [17]. However, there is still relatively little clinical data in China, and more evidence is needed to verify its role. Japanese researchers compared the efficacy of sequential surgical treatment with radiotherapy and direct surgical treatment in a group of patients with tumor thrombus in the main trunk or first-grade branches of the portal vein. Radiotherapy was directed only to the tumor thrombus, with a dose of 30-36 Gy in 10-12 times, and the surgery was performed within 2 weeks after radiotherapy. Postoperative pathological results showed that 5/6 (83.3%) patients in the radiotherapy sequential surgery group had complete necrosis of the thrombus in the main trunk of the portal vein. The 5-year survival rate was 34.8% in the radiotherapy sequential surgery group and 13.1% in the surgery alone group (P=0.0359)[18]. For patients with technically resectable CNLC stage IIIa hepatocellular carcinoma, Wei et al[19] compared the efficacy of preoperative radiotherapy sequential surgical resection with that of surgical resection alone by RCT, and found that the portal vein tumor thrombus was
downgraded from Cheng's type III to type II or from type II to type I in 20.7% of patients in the radiotherapy group, and that the survival of the patients was significantly improved by preoperative radiotherapy sequential surgical resection compared with surgical resection alone.

TACE is a commonly used treatment for unresectable hepatocellular carcinoma combined with PVTT, but whether it can be used in patients with PVTT type III/IV is still controversial, as it may lead to liver failure [34]. Currently, it is considered that TACE can be considered as long as liver function is acceptable and portal collateral circulation is already exists in the portal area [34]. The efficacy of TACE in treating PVTT is quite different [35], with the complete remission rate (CR) being 0, the partial remission rate (PR) being 19.5%-26.3%, and the stabilization rate (SD) being 42.5%-62.7%. The median survival of patients who respond to TACE is 13 months, and that of patients who do not respond is 5 months. The median survival of patients with liver function Child-Pugh class A is 15 months, and that of Child-Pugh class B is only 5 months. Therefore, it is recommended that TACE be used in combination with other therapies.

The role of TACE in conversion therapy has been explored and widely recognized. However, it should be noted that repeated TACE may lead to liver damage, which may affect the safety of hepatic resection after conversion. In the future, the success rate of conversion can be improved by improving the TACE treatment modality or combination therapy.

Inflammatory and non-inflammatory categories and genomic features of HCC are linked to immune checkpoint inhibitor response, but there are no validated biomarkers that can be used to guide clinical decision [20,21]. For patients with UR-HCC, sorafenib, a multi-kinase inhibitor, had been the only option of systemic therapy for a long time [22]. However, despite the widespread use of sorafenib in patients with UR-HCC, there were few reports of CS after sorafenib treatment. With the recent development of systemic therapy, a paradigm shift has occurred in the treatment of UR-HCC. In the phase 3 trial, several drugs were reported to be superior to sorafenib [23]. The REFLECT trial showed that lenvatinib was superior to sorafenib in terms of its tolerability and tumor response with an objective response rate of 24.1% versus 9.2% for sorafenib [24]. The IMbrave 150 trial showed that Atez+Bev has better disease control rate (Atez+Bev;73.6% versus Sorafenib; 55.3%) and improves long-term prognosis than sorafenib. The development of these effective agents has also expanded the potential of CS for UR-HCC. In this case, 7 months after the start of Atez+Bev, the peritoneal dissemination disappeared, and the patient no longer had an unresectable factor.

In this case, after 7 cycles of treatment with atezolizumab combined with bevacizumab and icaritin soft capsules, it was shown that the tumor gradually shrank, the portal vein tumor thrombus and the hepatic vein tumor thrombus gradually regressed, and the activity decreased, which made surgical resection possible. In fact, several CS cases after Atez+Bev or lenvatinib have been reported. Hidaka et al. reported CS after treatment with Atez+Bev for HCC with portal vein tumor thrombus [25]. Hoshino et al. reported the case of a HCCv15 cm in diameter occupying the right lobe with adrenal metastasis and invasion of the inferior vena cava, treated with 9 courses of Atez+Bev followed by CS [26]. Shindoh et al. reported 16 cases of CS after lenvatinib among 107 cases that were initially UR-HCC. Thus, an increasing number of
cases are being reported in initially UR-HCC can be resected following targeted therapies and immunotherapy, contributing to a prolonged prognosis. However, evidence-based data on the timing of surgery, surgical procedures, postoperative complications, postoperative recurrence time, and long-term prognosis in these patients are lacking. Although liver resection after conversion therapy is considered more difficult and more complicated than normal liver resection, CS can be performed safer with accurate preoperative evaluation (especially whether R0 can be achieved or not), precise intraoperative technique, and careful control of bleeding. Further follow-up is needed for recurrence and long-term survival after CS [27]. Controlling adverse events through systemic therapy is also an extremely important factor in achieving conversion surgery. We should pay attention to the use of ICIs in patients with autoimmune diseases, interstitial pneumonias, or a history of organ transplantation. In this case, only a transient transaminase elevation occurred throughout the course of treatment.

In this case, the patient used Epimedium soft capsule which can directly inhibit the proliferative activity of tumor cells, inhibit cell proliferation and promote apoptosis [28,29]. Icariin has anticancer effects both in vitro and in vivo. Its mechanism of action may be related to its antiangiogenic and antiproliferative effects in tumors [30]. Its antiangiogenic effect may mechanistically enhance the effect of targeted therapeutic agents. In vivo experiments in the present study demonstrated that icaritin could modulate immune cells in both bone marrow and peripheral blood[29]. Inhibition of PD-L1 expression by targeting protein IκB kinase α [31]. Icaritin inhibits PD-L1 expression by targeting protein IκB kinase α [32]. Icaritin reverses multidrug resistance in HepG2/ADR human hepatocellular carcinoma cells by down-regulating the expression of MDR1 and P-glycoprotein[33].

Conclusion

We report a case of giant hepatocellular carcinoma combined with portal vein tumor thrombus and inferior vena cava tumor thrombus treated with TACE, radiotherapy and atilizumab + bevacizumab + icaritin soft capsule followed by conversion surgery. The patient underwent R0 resection and the pathological results showed no residual surviving HCC. The patient survived without recurrence for 7 months.

Declarations

Ethical Approval

The study was approved by the ethics committee of Xijing Hospital, Air Force Military Medical University. Written informed consent was obtained from the patient to have the case details and any accompanying images published.

Competing interests

The authors declare that they have no competing interests.
Authors' contributions

TKS developed the main concept. SWJ and XJ wrote the main manuscript text. NY, LWM, YL and LJP collected clinical information. WMQ prepared figures 1.3.5. All authors reviewed the manuscript.

Funding

No funding was received.

Availability of data and materials

The original data presented in the study are included in the article, further inquiries can be directed to the corresponding author.

References


34. CHUNG GE LEE JH KIM HY et al Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival J Radiology 2011 258(2): 627 634


**Figures**
Figure 1

Legend not included with this version
Figure 2

Legend not included with this version
Figure 3

Legend not included with this version

Figure 4

Legend not included with this version
Figure 5

Legend not included with this version

Treatment profile

- admitting diagnosis
- TACE: Lobaplatin 50mg
- TACE: Pva embolized microspheres (medicine carrying pirarubicin 40mg)
- surgery

2022.4 2022.4.25 2022.6.9 2022.6.20 2022.8.17 2022.11 follow-up visit

- Radiotherapy: 50gy, 18 times
- atezolizumab + bevacizumab + icarin soft capsules, 7 times

Figure 6

Legend not included with this version